return equiti ttm
post-cal updat solid start expect year gradual
labcorp report first-quart result larg line estim rais
guidanc modestli bottom line revenu billion miss
billion target beat consensu billion adjust ep best
target consensu
covanc cdd result highlight ttm book-to-bil modest pullback
year-end constant-curr revenu growth basi
point margin expans primarili organ growth launchpad save
compani remain track deliv million chiltern cost synergi end
million net save cdd three-year launchpad initi
diagnost lcd revenu billion target billion
organ volum easili clear target contempl
substanti horizon share loss despit loss
revenu day basi point revenu per requisit decreas includ
pama headwind lcd oper margin fell basi point
driven primarili pama divestitur personnel cost cybersecur expens
somewhat off-set launchpad save
envigo transact labcorp purchas envigo non-clin contract research servic
busi sell envigo labcorp research model servic busi total
cash consider million labcorp gain increment million revenu
pro forma basi manag expect transact accret earn
cash flow year one set deliv million cost synergi year two
excess cost capit year three deal expect close midyear
incorpor guidanc second half
prefer lab network labcorp recent announc inclus unitedhealth
prefer lab network set go live juli importantli manag note
labcorp price chang part inclus pln
compani adjust guidanc account opportun expect
tighten referr network unit payer growth opportun
futur
labcorp second-largest independ clinic laboratori unit state nation network
primari laboratori patient servic center compani perform routin laboratori test
specimen day built lead platform esoter test
laboratori corpor america hold
pleas refer import disclosur page analyst certif page
william blair affili seek busi compani cover research report
result investor awar firm may conflict interest could affect object
report report intend provid person invest advic opinion recommend
herein take account individu client circumst object need intend
recommend particular secur financi instrument strategi particular client recipi
report must make independ decis regard secur financi instrument mention
manag left outlook larg intact increas adjust ep outlook
remain unchang outlook revenu growth inclus headwind divestitur
headwind currenc free cash flow million billion
lcd outlook unchang call revenu includ fx headwind neg impact
divestitur pama headwind lcd revenu growth first quarter compar full-year
guidanc basi point
cdd outlook unchang call revenu growth includ basi point fx headwind
estim estim includ revenu billion billion oper incom
billion billion adjust ep look revenu billion
adjust ep
share sit time adjust ep target three-year averag time view remain compel
long-term entri point continu believ compani effort build scale diversifi cro busi
leverag labcorp broad patient access lead higher revenu growth case covanc
independ diagnost side intrigu potenti rapidli grow walgreen
collabor continu believ earli inning secular shift market share lower-cost larger
lab given medicar reimburs pressur increas effort part privat payer reduc lab spend
strateg way compani face steepest year pama cut share loss expect stock
rerat gradual throughout year investor get comfort ep rang long-term growth outlook
maintain outperform rate
figur summar first-quart result versu estim includ
quarter reviewcurr actualprevi estimateprior year quarter million except per share covanc drug total y/i growth bp gross gross margin bp ebitda margin bp oper interest expense/ incom incom equiti pre-tax incom tax effect tax rate bp adjust net incom cont op average share outstand ep excl non rec item amort consensu estim currentrevenu per sourc compani report william blair compani estim factsetnot summari tabl line item adjust includ number may sum fav/ unfav varianc import disclosur
